Psoriasis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceu

DelveInsight's, "Psoriasis- Pipeline Insight, 2025" report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that over 80 leading companies are actively engaged in the development of more than 80 therapeutic candidates aimed at treating Psoriasis.

Psoriasis Overview: Overview

Psoriasis is a long-lasting inflammatory skin disorder influenced by genetic predisposition, environmental triggers, and immune system dysfunction. It is not contagious and affects approximately 2% of the global population. The severity of the disease varies, with skin involvement categorized as mild (less than 2%), moderate (2-10%), or severe (over 10%). The most prevalent form is chronic plaque psoriasis, or psoriasis vulgaris. This condition is driven by the activation of immune cells such as dendritic cells, T-cells, macrophages, neutrophils, and keratinocytes, resulting in the formation of characteristic skin lesions. For mild to moderate cases, topical therapies remain the primary treatment option.

Request for a detailed insights report on Psoriasis pipeline insights [https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Psoriasis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Psoriasis Therapeutics Market.

Key Takeaways from the Psoriasis Pipeline Report

*
DelveInsight's Psoriasis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Psoriasis treatment.

*
In October 2023, the FDA approved BIMZELX (bimekizumab-bkzx) for treating moderate to severe psoriasis in adults who are suitable candidates for systemic therapy or phototherapy. It is the first and only inhibitor of both IL-17A and IL-17F approved for treating adults with moderate to severe plaque psoriasis.

*
In October 2023, Arcutis Biotherapeutics announced that the FDA had approved a supplemental new drug application (sNDA) to expand the use of ZORYVE (roflumilast) cream 0.3% for topical treatment of plaque psoriasis, including areas with skin folds, for children aged 6 to 11 years.

*
In November 2020, Biohaven Pharmaceutical partnered with Weill Cornell Medicine to launch a clinical trial using a Biohaven CGRP-receptor antagonist for treating plaque psoriasis. CGRP, a neuropeptide, is thought to play a key role in the development of inflammatory skin conditions like psoriasis.

*
Key Psoriasis companies such as Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others are evaluating new drugs for Psoriasis to improve the treatment landscape.

*
Promising Psoriasis pipeline therapies in various stages of development include Topical roflumilast, GSK2982772, and others.

Psoriasis Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Psoriasis Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Psoriasis market.

Download our free sample page report on Psoriasis pipeline insights [https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Psoriasis Emerging Drugs

*
Topical roflumilast: Arcutis Biotherapeutics

*
GSK2982772: GlaxoSmithKline

Psoriasis Companies

More than 80 prominent companies are actively developing treatments for psoriasis. Among these, Biocad has the most advanced drug candidates, which have reached the registration stage.

DelveInsight's report covers around 80+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Psoriasis Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Psoriasis Therapies and Key Companies: Psoriasis Clinical Trials and advancements [https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Psoriasis Pipeline Therapeutic Assessment

- Psoriasis Assessment by Product Type

- Psoriasis By Stage

- Psoriasis Assessment by Route of Administration

- Psoriasis Assessment by Molecule Type

Download Psoriasis Sample report to know in detail about the Psoriasis treatment market @ Psoriasis Therapeutic Assessment [https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Psoriasis Current Treatment Patterns

4. Psoriasis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Psoriasis Late-Stage Products (Phase-III)

7. Psoriasis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Psoriasis Discontinued Products

13. Psoriasis Product Profiles

14. Psoriasis Key Companies

15. Psoriasis Key Products

16. Dormant and Discontinued Products

17. Psoriasis Unmet Needs

18. Psoriasis Future Perspectives

19. Psoriasis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Psoriasis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psoriasis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-mylan-biocad-bristolmyers-squibb-celltrion-coherus-biosciences-janssen-pharmaceu]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.